TABMELT Granted Patent Allowance in Israel, Expanding Vivera’s Global Licensing Reach
NEWPORT BEACH, Calif. — Vivera is pleased to announce the expansion of its exclusive global license to the novel TABMELT® platform for pharmaceutical use in Israel. This latest patent allowance by the Israel Patent Office (ILPO) follows international TABMELT patent grants in Canada, Russia, Australia, and the United Kingdom. “Receiving the TABMELT patent allowance from […]
Vivera Enters $6B Market with Speech Assessment and Feedback Device Patent Allowance
NEWPORT BEACH, Calif.—Vivera is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has issued a U.S. patent allowance for the Company’s Speech Fluency Evaluation and Feedback method and device. Stuttering, a speech disorder characterized by speech disfluencies, affects 70 million patients worldwide. While there is no cure for stuttering, there are treatment options […]
Vivera Welcomes Healthcare Founder and CEO Lea Ramirez to its Advisory Board
NEWPORT BEACH, Calif. – Vivera is pleased to welcome Lea Ramirez to the Company’s Advisory Board. Ms. Ramirez joins Vivera’s Advisory Board to assist with healthcare strategy and planning as the Company works on its shorter and longer-term commercialization strategies and projects. Ms. Ramirez started her career in the banking industry, serving as a regional […]
Vivera Appoints World-Renowned Regulatory Leader Dr. Geetha Rao to Advisory Board
NEWPORT BEACH, Calif—Vivera is pleased to welcome Dr. Geetha Rao to the Company’s Advisory Board as its Regulatory Advisor. Dr. Rao will guide Vivera through its regulatory pathway for its medical device and technology products, ZICOH and MDZone. Dr. Rao is an entrepreneur, executive, and strategic advisor on medical devices, health information technology, and connected […]
Vivera Calls for Better Solutions Amidst $1.5 Trillion Opioid Addiction Crisis Economic Burden
NEWPORT BEACH, Calif.— Vivera invites congress members combatting the opioid crisis to discuss response and prevention solutions. A recently released congressional Joint Economic Committee (JEC) report estimates that opioid addiction has cost the United States nearly $1.5 trillion in 2020—indicating a 37% increase since 2017. According to the JEC report, the pandemic is responsible for […]
VIVERA FILES RESPONSE DEFENDING ITSELF AGAINST THE SEC’S RECENT THREAT OF A CIVIL SUIT
NEWPORT BEACH, Calif. – (September 30, 2022) – Vivera Pharmaceuticals, Inc. (“Vivera”) announces that it has responded to a recent Wells Notice from the Los Angeles Staff of the U.S. Securities and Exchange Commission (“SEC”) that threatens a civil lawsuit against the Company. Vivera notified the SEC in advance that any such lawsuit by the […]
Vivera Receives 3rd Patent for ZICOH, Expanding Into $500B Prescription Market
NEWPORT BEACH, Calif.—Vivera is pleased to announce the U.S. Patent and Trademark Office (USPTO) has granted a third U.S. Patent, No. 11,450,420, for ZICOH, securing the device’s rights as a Secure Smart Dosing System with Automated Delivery, Measurement, and Management for Pills. With a goal to end prescription drug misuse while improving patient prescription adherence, […]
Vivera Supports Terrorist Attack Exercise for OC Law Enforcement and Fire Authority
Last month, Vivera was proud to support local, state, and federal law enforcement agencies and firefighters for a complex, coordinated terrorist attack exercise. The Company welcomed five public safety agencies to use its Mission Viejo location as the operational center for the training: the Orange County Sheriff’s Department, California Highway Patrol, the Orange County Fire […]
Fentanyl and the Current State of the Opioid Epidemic
Last year, our country hit a grim milestone. Overdose deaths surpassed 100,000 for the first time in a 12-month period. More than 64,000 of these deaths involved fentanyl, a synthetic opioid 80 to 100 times more potent than morphine. Today, fentanyl is the leading cause of death for adults aged 18-45, claiming more lives during […]
Opioid Settlements Reach Over $37 Billion. Vivera Provides First High-Tech Solution
NEWPORT BEACH, Calif.— Vivera extends an invitation to AbbVie’s Allergan to partner on its high-tech medical device, ZICOH, designed to end addiction, in light of the former opioid maker’s recently proposed $2.37 billion settlement for its alleged role in the opioid crisis. State and local governments sued Allergan, claiming that the Company deceptively marketed opioids […]
